Player FM 앱으로 오프라인으로 전환하세요!
PARPi de-escalation in ovarian cancer with Giuseppe Caruso
Manage episode 444138468 series 2474076
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Giuseppe Caruso to discuss PARPi de-escalation in ovarian cancer. Dr. Caruso is a gynecologist, currently working as a research fellow at Mayo Clinic, Division of Gynecological Surgery, in Rochester (MN, USA) under the supervision of Professor William Cliby. He is also a PhD fellow in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy and collaborates with the European Institution of Oncology in Milan (Italy) under the mentorship of Professor Nicoletta Colombo. His main areas of interest are ovarian cancer and precision oncology.
Highlights:
- Systemic therapy de-escalation is a new frontier in personalizing therapy for advanced ovarian cancer.
- PARPi are so effective that selected patients may require less systemic therapy to achieve the same outcomes.
- The fundamental key is to limit de-escalation to BRCAm/HRD-positive patients with R0 after surgery.
- Several de-escalation attempts are under investigation, but none is currently recommended outside of clinical trials.
386 에피소드
Manage episode 444138468 series 2474076
In this episode of the IJGC podcast, Editor-in-Chief Dr. Pedro Ramirez is joined by Dr. Giuseppe Caruso to discuss PARPi de-escalation in ovarian cancer. Dr. Caruso is a gynecologist, currently working as a research fellow at Mayo Clinic, Division of Gynecological Surgery, in Rochester (MN, USA) under the supervision of Professor William Cliby. He is also a PhD fellow in “Network Oncology and Precision Medicine” at Sapienza University of Rome in Italy and collaborates with the European Institution of Oncology in Milan (Italy) under the mentorship of Professor Nicoletta Colombo. His main areas of interest are ovarian cancer and precision oncology.
Highlights:
- Systemic therapy de-escalation is a new frontier in personalizing therapy for advanced ovarian cancer.
- PARPi are so effective that selected patients may require less systemic therapy to achieve the same outcomes.
- The fundamental key is to limit de-escalation to BRCAm/HRD-positive patients with R0 after surgery.
- Several de-escalation attempts are under investigation, but none is currently recommended outside of clinical trials.
386 에피소드
모든 에피소드
×플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.